Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients-Reference-Cited by-同舟云学术

Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients

Published:2020-11-11 Issue:3 Volume:26 Page:543-551
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Takeda Tsuyoshi,Sasaki Takashi^ORCID,Fukuda Koshiro,Mie Takafumi,Furukawa Takaaki,Yamada Yuto,Kasuga Akiyoshi,Matsuyama Masato,Ozaka Masato,Sasahira Naoki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-020-01827-2.pdf

Reference30 articles.

1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30

2. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

3. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

4. Barenboim A, Lahat G, Geva R et al (2018) Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 44(10):1619–1623

5. Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264(3):457–463

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system;International Journal of Clinical Pharmacy;2023-12-15

2. Accurate Evaluation and Treatment of Dyspnea in Patients with Gastrointestinal Cancer;Journal of Digestive Cancer Research;2023-08-20

3. Gemcitabine plus nab‐paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study;Cancer Science;2023-08-07

4. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan;BMC Cancer;2023-04-06

5. Incidence and appropriate management of drug‐induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study;Asia-Pacific Journal of Clinical Oncology;2022-12-07